Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Assessing Vaccine Effectiveness of R21/Matrix-M Across Malaria Transmission Settings (AVERT) (AVERT)

3 augusti 2026 uppdaterad av: Clinton Health Access Initiative Inc.

Real-World Effectiveness of the R21/Matrix-M Malaria Vaccine in Children in Burkina Faso and Uganda

The AVERT study is a prospective observational test-negative case control study evaluating the real-world effectiveness of the R21/Matrix-M malaria vaccine among children younger than 5 years in Burkina Faso and Uganda. Children who seek outpatient care with suspected malaria and are eligible for the national R21/Matrix-M vaccination program will be enrolled. Malaria infection will be determined by blood smear microscopy. Children with a positive microscopy result will be classified as cases and children with a negative result as controls. Vaccination history, including the number and timing of doses, will be obtained primarily from vaccination cards or other written records. Vaccine effectiveness will be estimated by comparing the odds of vaccination among cases and controls.

Studieöversikt

Status

Rekrytering

Betingelser

Intervention / Behandling

Detaljerad beskrivning

R21/Matrix-M has been introduced through national immunization programs, but its effectiveness under routine conditions may differ from efficacy observed in clinical trials because children may receive different numbers of doses, doses may be delayed, protection may wane, and malaria transmission and other prevention measures vary across settings.

AVERT will use a prospective test-negative case-control design at approximately 22 outpatient health facilities in moderate- to high-transmission areas of Burkina Faso and Uganda. Consecutive children younger than 5 years who meet country definitions for suspected malaria, are eligible for R21/Matrix-M vaccination, and have caregiver consent will be enrolled. All participants will undergo malaria testing as part of routine care, with study blood smear microscopy used to assign case or control status. A structured caregiver questionnaire will collect demographic, clinical, residential, socioeconomic, health-care access, and malaria-prevention information. R21/Matrix-M dose number and vaccination dates will be verified primarily from vaccination cards, individual health records, or facility vaccination registers.

Cases and controls will be matched, when feasible, by geographic area and calendar time. Conditional or standard logistic regression will estimate adjusted odds ratios comparing vaccinated and unvaccinated children, and vaccine effectiveness will be calculated as (1 - adjusted odds ratio) x 100%. Analyses will be conducted separately by country and will assess effectiveness by dose, time since vaccination, dose spacing, transmission intensity, sex, and use of seasonal malaria chemoprevention, insecticide-treated nets, and indoor residual spraying. A health-system-perspective economic evaluation will estimate incremental cost per uncomplicated clinical malaria case averted.

Studietyp

Observationell

Inskrivning (Beräknad)

20000

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

  • Burkina Faso
    • Boucle Mouhoun
      • Boromo, Boucle Mouhoun, Burkina Faso
        • Rekrytering
        • Boromo urbain 1
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Boromo, Boucle Mouhoun, Burkina Faso
        • Rekrytering
        • Ouahabou
        • Kontakt:
    • Hauts-Bassins Region
      • Houndé, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Béréba
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Houndé, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Dohoun
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Houndé, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Kari
        • Kontakt:
          • Halidou Tinto
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Déguélin
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Karangasso-Vigué
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Sourmousso
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Karangasso-Vigué, Hauts-Bassins Region, Burkina Faso
        • Rekrytering
        • Wara
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
    • Oubri
      • Zorgo, Oubri, Burkina Faso
        • Rekrytering
        • Mankarga T
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Zorgo, Oubri, Burkina Faso
        • Rekrytering
        • Mankarga V3
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
      • Zorgo, Oubri, Burkina Faso
        • Rekrytering
        • Mankarga V6
        • Kontakt:
          • Halidou Tinto, PhD
          • Telefonnummer: +226 25 40 92 12
          • E-post: tintoh@crun.bf
  • Uganda
    • Acholi
      • Kitgum, Acholi, Uganda
        • Har inte rekryterat ännu
        • Kitgum-Matidi HCIII
        • Kontakt:
      • Kitgum, Acholi, Uganda
        • Har inte rekryterat ännu
        • Namokora HCIV
        • Kontakt:
      • Omoro, Acholi, Uganda
        • Har inte rekryterat ännu
        • Lalogi HCIV
        • Kontakt:
    • Bunyoro
      • Kikube, Bunyoro, Uganda
        • Har inte rekryterat ännu
        • Rwenyawawa HCIII
        • Kontakt:
    • Busoga
      • Kaliro, Busoga, Uganda
        • Har inte rekryterat ännu
        • Nawaikoke HCIII
        • Kontakt:
      • Mayuge, Busoga, Uganda
        • Har inte rekryterat ännu
        • Kigandalo HCIV
        • Kontakt:
    • Karamoja
      • Moroto, Karamoja, Uganda
        • Har inte rekryterat ännu
        • Nadunget HCIII
        • Kontakt:
    • Lango
      • Otuke, Lango, Uganda
        • Har inte rekryterat ännu
        • Orum HCIV
        • Kontakt:
      • Oyam, Lango, Uganda
        • Har inte rekryterat ännu
        • Otwal HCIII
        • Kontakt:

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

  • Barn

Tar emot friska volontärer

Nej

Testmetod

Icke-sannolikhetsprov

Studera befolkning

Children younger than 5 years who reside in the catchment areas of selected health facilities in R21/Matrix-M implementation districts in Burkina Faso or Uganda, are age-eligible for vaccination under the relevant national schedule, and present for outpatient care with suspected malaria. Participants are recruited from health facilities in moderate- to high-transmission settings.

Beskrivning

Inclusion Criteria:

  • Residence in an area where R21/Matrix-M is implemented and within the catchment area of a selected study facility.
  • Younger than 5 years and eligibleto receive R21/Matrix-M under the national vaccination schedule at rollout.
  • Meets the country definition of suspected malaria, generally axillary temperature of at least 37.5 degrees Celsius or a history of fever within the previous 24 hours, and is undergoing malaria testing.
  • Written informed consent provided by an adult caregiver aged 18 years or older.

Exclusion Criteria:

  • Caregiver is unable or unwilling to provide informed consent.
  • Severe non-malaria illness at presentation that would interfere with study participation.
  • Repeat presentation within the protocol-defined exclusion window after a previous enrollment: within 14 days after a microscopy-positive visit; or more than 7 but fewer than 14 days after a microscopy-negative visit. A microscopy-negative visit followed by a positive diagnosis within 7 days will be reclassified as positive rather than treated as a new enrollment.
  • Documented receipt of any RTS,S malaria vaccine dose.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

Kohorter och interventioner

Grupp / Kohort
Intervention / Behandling
Suspected malaria cases that test positive using microscopy
Eligible children with suspected malaria whose enrollment blood smear microscopy result is positive for P. falciparum infection
Biologisk: R21/Matris-M Malaria vaccine
R21/Matrix-M vaccination received through routine national immunization programs. The study will record the number and dates of doses received. Children will be classified as having received 0, 1, 2, 3, or 4 eligible doses, with prespecified grouped classifications used if individual dose categories are underpowered. Doses given fewer than 14 days before malaria testing will not count toward the primary exposure classification.
Suspected malaria cases that test negative using microscopy
Eligible children with suspected malaria whose enrollment blood smear microscopy result is negative for P. falciparum infection
Biologisk: R21/Matris-M Malaria vaccine
R21/Matrix-M vaccination received through routine national immunization programs. The study will record the number and dates of doses received. Children will be classified as having received 0, 1, 2, 3, or 4 eligible doses, with prespecified grouped classifications used if individual dose categories are underpowered. Doses given fewer than 14 days before malaria testing will not count toward the primary exposure classification.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Dose-specific effectiveness of R21/Matrix-M against microscopy-confirmed clinical malaria
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month study recruitment period
Adjusted vaccine effectiveness will be calculated as (1 - adjusted odds ratio) x 100%. The odds ratio will compare the odds of each documented R21/Matrix-M dose category among microscopy-positive malaria cases with the odds among microscopy-negative controls, using children with 0 doses as the primary reference group. Prespecified grouped dose categories will be used if individual dose categories do not have adequate statistical power.
At the enrollment illness episode, during the approximately 7- to 8-month study recruitment period

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Effectiveness of R21/Matrix-M by time since vaccination
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Adjusted vaccine effectiveness will be estimated by categorical and/or continuous time since the most recent eligible vaccine dose, including interactions between dose and time.
At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Effect modification of vaccine effectiveness by malaria transmission intensity
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Dose-specific vaccine effectiveness will be compared across prespecified malaria transmission levels within each country.
At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Effect modification of vaccine effectiveness by sex
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Dose-specific vaccine effectiveness will be estimated using vaccination-by-sex interaction terms and sex-stratified analyses.
At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Effect modification by other malaria prevention interventions
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Dose-specific vaccine effectiveness will be assessed in relation to seasonal malaria chemoprevention, insecticide-treated net use, and indoor residual spraying using interaction analyses.
At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Effectiveness according to vaccine dose timing
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Among vaccinated children, effectiveness will be compared for on-time and late vaccination and in analyses restricted to doses spaced 3 to 5 weeks apart. A late dose is defined as a dose received at least 2 weeks after the scheduled date.
At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Effectiveness of the fourth dose relative to the three-dose primary series
Tidsram: At the enrollment illness episode, during the approximately 7- to 8-month recruitment period
Adjusted vaccine effectiveness of 4 doses compared with 3 doses will be estimated using the odds of microscopy-confirmed malaria.
At the enrollment illness episode, during the approximately 7- to 8-month recruitment period

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Clinton Health Access Initiative Inc.

Samarbetspartners

University of California, San Francisco
Institut de Recherche en Sciences de la Sante, Burkina Faso
Ministry of Health, Uganda
Ministry of Health, Burkina Faso
Infectious Diseases Research Collaboration, Uganda

Utredare

  • Huvudutredare: Isabel Rodriguez-Barraquer, MD, PhD, University of California, San Francisco
  • Huvudutredare: Halidou Tinto, PhD, Institut de Recherche en Sciences de la Santé (Burkina Faso)
  • Huvudutredare: Joaniter Nankabirwa, MD, PhD, Infectious Diseases Research Collaboration, Kampala, Uganda

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

14 juli 2026

Primärt slutförande (Beräknad)

1 juni 2027

Avslutad studie (Beräknad)

1 augusti 2027

Studieregistreringsdatum

Först inskickad

3 augusti 2026

Först inskickad som uppfyllde QC-kriterierna

3 augusti 2026

Första postat (Faktisk)

6 augusti 2026

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

6 augusti 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

3 augusti 2026

Senast verifierad

1 augusti 2026

Mer information

Termer relaterade till denna studie

Nyckelord

Ytterligare relevanta MeSH-villkor

Andra studie-ID-nummer

  • AVERT-2026-01
  • INV-097482 (Annat bidrag/finansieringsnummer: Gates Foundation)
  • 2026-06-05 (Annat bidrag/finansieringsnummer: Givewell)

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

OBESLUTSAM

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Nej

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera